Neoleukin Therapeutics

Neoleukin Therapeutics: Lead product candidate, NL-201, is a de novo protein designed to mimic the therapeutic activity of IL-2 and IL-15 for the treatment of cancer. NL-201 is designed to eliminate binding to the alpha subunit of the IL-2/CD25 receptor while maintaining high-affinity binding to the beta and gamma subunits. Phase 1 clinical trial of NL-201 is ongoing and the company is expecting interim data in 1H2022.
Healthcare/Drug Manufacturers
Based in...
US - Pacific
Clinical Stage
Pre-Clinical Stage
Disease Space
Allergy, Autoimmune, Immuno-Oncology, Infectious Disease, Oncology
Public, USA
Market Cap
100MM - 500MM
1616 Eastlake Avenue E
Suit 360
Seattle, WA 98109
United States

Company Participants at Solebury Trout Hamptons CEO Roundtable 2021

  • Jonathan G. Drachman, Pres/CEO

Top 10 Holders of Neoleukin Therapeutics, Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Redmile Group LLC 9.26 3,919,235 29.75 13F 6/30/21
Baker Bros. Advisors LP 9.03 3,821,740 29.01 13F 6/30/21
Ecor1 Capital LLC 5.57 2,358,804 17.90 13F 6/30/21
Pictet Asset Management Ltd. 4.83 2,043,896 15.51 13F 6/30/21
Pictet Asset Management SA 3.97 1,671,419 12.69 Funds 3/31/21
The Vanguard Group, Inc. 3.77 1,597,243 12.12 Funds 7/31/21
BlackRock Fund Advisors 3.76 1,592,395 12.09 13F 6/30/21
Vanguard Group, Inc. (Subfiler) 3.61 1,527,601 11.59 13F 6/30/21
Boxer Capital LLC 3.54 1,501,058 11.39 13F 6/30/21
State Street Corp. 2.92 1,235,098 9.37 13F 6/30/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.